Alza Corporation

Sinusys Corporation

Other

Xenoport, Inc.

Alza Corporatiton

David E Edgren

Gurdish K Bhatti

Atul D Ayer

Felix T Theeuwes

Patrick S-l Wong

Liang C Dong

Thomas A Schreck

Jerome Hester

Curtis Leslie Rieser

Howard A Carpenter

Patrick S Wong

Judy A Magruder

William Jason Fox

Robert R Skluzacek

Vincent Joseph Ferrari

William L Gould

Francisco Jao

Liang-Chang Dong

Shu W Li

Bradley F Marple

Patrick S L Wong

David R Swanson

Paul R Magruder

Patrick S -l Wong

Maureen L Jordan

Andrew C Lam

Michael A DesJardin

Brenda J Pollock

Evangeline Cruz

Noymi Yam

Phyllis I Gardner

Padmanabh Bhatt

Si-Hong Yum

Crystal Pollock-Dove

Phillip R Nixon

Sylvia L Seroff

Jason J Wan

Gregory Ruhlmann

Sherry Li

Carmelita Garcia

Alfredo M Wong

Ryan Bronz

Tracy Fink

Zahedeh Hatamkhani

Gregory C Ruhlmann

Su Il Yum

Eun Soo Lee

Brian L Barclay

Ye Huang

Andrew Ivan Poutiatine

Nikhil Pargaonkar

Yolanda M Puga

Brenda Pollock

David J Kidney

Derrick K Kim

Gorm Yoder

Sarni Karaborni

Larry G Hamel

Patrick SL Wong

Sustained release oral dosage forms of an R-baclofen prodrug are disclosed.

Sustained release oral dosage forms of an R-baclofen prodrug

Devices that are adapted to insert a sinus dilator into a stenotic opening of a paranasal sinus of a subject using minimally invasive dilator insertion procedures are provided. The devices and methods can be used to treat sinusitis and other nasal and/or sinus disorders.

Devices and methods for inserting a sinus dilator

Medical devices which are adapted to be implanted into a patient for a limited period of time using minimally invasive insertion procedures for dilating a stenotic opening, such as a stenotic sinus opening, are provided. The devices and methods can be used for treating sinusitis and other nasal and/or sinus disorders.

Devices and methods for dilating a paranasal sinus opening and for treating sinusitis

Medical devices which are adapted to be inserted into a patient for a limited period of time using minimally invasive insertion procedures for dilating a stenotic opening, such as a stenotic sinus opening, are provided. The devices and methods can be used for treating sinusitis and other nasal and/or sinus disorders.

A membrane system comprising an interior wall, a fluid-permeable exterior wall surrounding the interior wall and an internal compartment defined by the membrane system, wherein fluid permeability of the interior wall is responsive to osmolarity of an osmotic core within the internal compartment are disclosed. A controlled release dosage form comprising the membrane system and a process for delivering an osmotically active formulation from an osmotic pump over an extended period of time are also disclosed.

Extended release dosage form

Aqueous drug coatings including at least one insoluble drug, wherein the insoluble drug accounts for about 85 wt % to about 97 wt % of the drug coatings are described. Such drug coatings may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs.

Drug coating providing high drug loading

The present invention is directed to aqueous drug coatings that include at least one insoluble drug, wherein the drug accounts for about 85 wt % to about 97 wt % of the drug coatings. A drug coating according to the present invention may include only one insoluble drug, two or more insoluble drugs, or one or more insoluble drugs in combination with one or more soluble drugs. The present invention also includes drug coating formulations suitable for providing drug coatings according to the present invention and dosage forms that include a drug coating according to the present invention.

Drug coating providing high drug loading and methods for providing the same

The invention pertains to a dosage formand to administering an antidepressant medicamentfor an extended period of time in a rate-known dose.

Antidepressant dosage form

A composition is disclosed comprising a polymer and a surfactant in a solvent exhibiting a common solubility for the polymer and the surfactant. The composition provides a dosage form for administering a drug over time.

Pharmaceutical coating composition and method of use

The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, formed of polymer matrices that swell upon contact with the fluids of the stomach. At least one layer of the multilayered dosage form includes an active agent. A portion of the polymer matrices are surrounded by a band of insoluble material that prevents the covered portion of the polymer matrices from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Gastric retention dosage form having multiple layers

The present invention is directed to an active agent dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of a liquid, active agent formulation to a fluid environment of use. The liquid, active agent formulation is sorbed into porous particles that are dispersed in a polymer matrix that swells upon contact with the fluids of the stomach. A portion of the polymer matrix may be surrounded by a band of insoluble material that prevents the covered portion of the polymer matrix from swelling and provides a segment of the dosage form that is of sufficient rigidity to withstand the contractions of the stomach and delay expulsion of the dosage form from the stomach until substantially all of the active agent has been dispensed.

Gastric retaining oral liquid dosage form

Growing community of inventors

El Granada, CA, United States of America

David E Edgren